Want to get this daily news briefing by email? Here’s the sign-up.
WHAT WE’RE WATCHING
POST-VERDICT – With a $572 million bench verdict in Oklahoma against Johnson & Johnson opioid maker Janssen Pharmaceuticals, pro-business groups are taking issue with the legal basis for the state’s win and fretting over its impact, should the judgment stand. Amanda Bronstad reports that the outcome of closely-watched trial, which has preceded an MDL trial in October with more than 20 defendants, has defense groups worried about expanding the public nuisance doctrine, the basis for liability found by Oklahoma Judge Thad Balkman. Such an interpretation of public nuisance means “almost any industry could be the target of large-scale litigation,” said Lisa Rickard, president of the U.S. Chamber’s Institute for Legal Reform.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
